Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-134211

Published: 2020

Journal Articles

Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia

Katherine Tarlock, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Quy Le, PhD, Thao T. Tang, Darcy Hamill, DO, Anilkumar Gopalakrishnapillai, PhD, Sonali Barwe, PhD MSc, Rhonda E. Ries, MA, Richard Aplenc, MD PhD, Andrew C. Wood, MD, E. Anders Kolb, MD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134821

Published: 2020

Journal Articles

Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access

Katherine Tarlock, MD, Soheil Meshinchi, MDPhD, Jeffrey E. Rubnitz, MD, Seth E. Karol, MD, Barbara Spitzer, MD, Amit J. Sabnis, MD, Asif Pathan, PhD RPh, Boo Messahel, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-140399

Published: 2020

Journal Articles

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

Jessica A. Pollard, MD, Todd A. Alonzo, PhD, Patrick A. Brown, MD, Robert B. Gerbing, Elizabeth Fox, MD, John Kim Choi, MD, Brian T. Fisher, DO, MSCE, Betsy A Hirsch, PhD, Samir Kahwash, MD, John E. Levine, MDMS, Michael R. Loken, PhD, Susana C. Raimondi, PhD, Katherine Tarlock, MD, Andrew C. Wood, MBCHB, Lillian Sung, MD PhD, Anders E. Kolb, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Richard Aplenc, MD PhD

Blood (2019) 134 (Supplement_1): 292.

https://doi.org/10.1182/blood-2019-129557

Published: 2019

Journal Articles

Response to Sorafenib in FLT3 /ITD AML Is Depedent on Co-Occurring Mutational Profile

Katherine Tarlock, MD, Jessica A. Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, MA, Jenny L. Smith, MSc, MD, E. Anders Kolb, MD, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 119.

https://doi.org/10.1182/blood-2019-127569

Published: 2019

Journal Articles

Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation

Katherine Tarlock, MD, Todd A. Alonzo, PhD, Yi-Cheng Wang, Robert B. Gerbing, Rhonda E. Ries, MA, Tiffany A. Hylkema, BS, William G. Woods, MD, Todd M Cooper, DO, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 181.

https://doi.org/10.1182/blood-2019-126273

Published: 2019

Journal Articles

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

Katherine Tarlock, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Yi-Cheng Wang, Robert B. Gerbing, Laura Pardo, Fangyan Dai, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Jessica A. Pollard, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 2699.

https://doi.org/10.1182/blood-2019-127100

Published: 2019

Journal Articles

Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Ann Dahlberg, MD, Muna Qayed, MDMSc, Katherine Tarlock, MD, Jessica A. Pollard, MD, Filippo Milano, MD PhD, Soheil Meshinchi, MD PhD, Colleen Delaney, MD MSc

Blood (2019) 134 (Supplement_1): 2614.

https://doi.org/10.1182/blood-2019-130979

Published: 2019

Journal Articles

Distinct Co-Occurring Mutational Profiles in Acute Myeloid Leukemia Confers Prognostic Significance in Children and Young Adults with FLT3 /ITD Mutations

Katherine Tarlock, MD, Todd A Alonzo, PhD, Robert B Gerbing, MA, Rhonda E. Ries, MA, Brenda Gibson, MD PhD, Naghmeh Niktoreh, Sanne Noort, MD MSc, Marry M. Van den Heuvel-Eibrink, MD, C. Michel Zwaan, MD PhD, Soheil Meshinchi, MD PhD

Blood (2018) 132 (Supplement 1): 443.

https://doi.org/10.1182/blood-2018-99-113676

Published: 2018

Journal Articles

Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate

Allison Kaeding, MD, Katherine Tarlock, MD, E. Anders Kolb, MD, Soheil Meshinchi, MD PhD

Blood (2018) 132 (Supplement 1): 1448.

https://doi.org/10.1182/blood-2018-99-110845

Published: 2018

Journal Articles

CD33 SNP Genotype and Splice Variation Are Associated with CD33 Cell Surface Expression and SGN-CD33A Pharmacokinetics

Katherine Tarlock, MD, Zixing Wang, Rory Rohm, Travis Biechele, Rhonda E. Ries, MA, Tiffany Hylkema, BS, Jatinder K Lamba, PhD, Gary D Means, PhD, Robert Thurman, Bill Arthur, Soheil Meshinchi, MD PhD

Blood (2018) 132 (Supplement 1): 3942.

https://doi.org/10.1182/blood-2018-99-113932

Published: 2018

Journal Articles

Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium

Blood (2018) 132 (Supplement 1): 2710.

https://doi.org/10.1182/blood-2018-99-116908

Published: 2018

Journal Articles

Synergistic Effect of SGN-CD33A and FLT3 Inhibitors in FLT3 /ITD Acute Myeloid Leukemia

Katherine Tarlock, MD, Robert Thurman, Rory Rohm, Travis Biechele, Bill Arthur, Soheil Meshinchi, MD PhD

Blood (2018) 132 (Supplement 1): 2723.

https://doi.org/10.1182/blood-2018-99-116466

Published: 2018

Journal Articles

Recurrent Copy Number Variants Are Highly Prevalent in Acute Myeloid Leukemia

Katherine Tarlock, MD, Yuting He, James Sun, Rhonda E. Ries, MA, Eric A Severson, MD PhD MMSc, Mark Bailey, MS, Samantha Morley, PhD, Sohail Balasubramanian, Rachel Erlich, PhD, Doron Lipson, PhD, Geoff Otto, PhD, Jo-Anne Vergillo, Jeffrey S Ross, MD, Tariq Mughal, FRCP, Phil Stephens, PhD, Vincent Miller, MD, Soheil Meshinchi, MD PhD, Jie He, PhD

Blood (2017) 130 (Supplement 1): 3800.

https://doi.org/10.1182/blood.V130.Suppl_1.3800.3800

Published: 2017

Journal Articles

Barriers to Successful Implementation of Precision Medicine to the Treatment of Refractory AML: Lessons Learned

Blood (2017) 130 (Supplement 1): 4622.

https://doi.org/10.1182/blood.V130.Suppl_1.4622.4622

Published: 2017

Journal Articles

CD33 DE2 Transcript Variant Encoded By Splicing Polymorphism Is Devoid of Antibody Binding Site and Lacks Response to CD33 Directed Antibody Drug Conjugates

Katherine Tarlock, MD, Jatinder Lamba, PhD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 2661.

https://doi.org/10.1182/blood.V130.Suppl_1.2661.2661

Published: 2017

Journal Articles

Prolonged Azacitidine Exposure Alters Immunophenotype in Myeloid Leukemia Cell Lines

Allison Kaeding, MD, Laura Pardo, Michael R. Loken, PhD, Lisa E. Brodersen, PhD, Katherine Tarlock, MD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 2619.

https://doi.org/10.1182/blood.V130.Suppl_1.2619.2619

Published: 2017

Journal Articles

Functional Properties of Exon 17 KIT Mutations in Pediatric CBF AML Predict for Inferior Outcome and Enhanced Response to Tyrosine Kinase Inhibition: A Report from the Children's Oncology Group

Katherine Tarlock, MD, Todd A Alonzo, PhD, Robert B Gerbing, Yi-Cheng Wang, Rhonda E. Ries, MA, Tiffany Hylkema, BS, Jason Joaquin, Susana C. Raimondi, PhD, Betsy A Hirsch, PhD, Edward A Kolb, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Jessica A. Pollard, MD

Blood (2017) 130 (Supplement 1): 25.

https://doi.org/10.1182/blood.V130.Suppl_1.25.25

Published: 2017

Journal Articles

Functional Evaluation and Clinical Implications of FLT3 J uxtamembrane Domain Short Variants in Pediatric AML

Katherine Tarlock, MD, Todd A Alonzo, PhD, Yi-Cheng Wang, Robert B Gerbing, Tiffany Hylkema, BS, Rhonda E. Ries, MA, M. Eva Hansen, Edward A Kolb, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 2664.

https://doi.org/10.1182/blood.V130.Suppl_1.2664.2664

Published: 2017

Journal Articles

Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia

Allison Kaeding, MD, Katherine Tarlock, MD, Sonali Barwe, PhD, Anilkumar Gopalakrisnapillai, PhD, Todd A Alonzo, PhD, Robert B Gerbing, Michael R. Loken, PhD, Rhonda E. Ries, MA, Laura Pardo, Cassie Chou, MD PhD, E. Anders Kolb, MD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 2641.

https://doi.org/10.1182/blood.V130.Suppl_1.2641.2641

Published: 2017

NARROW

Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG

Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia

Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

Response to Sorafenib in FLT3 /ITD AML Is Depedent on Co-Occurring Mutational Profile

Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Distinct Co-Occurring Mutational Profiles in Acute Myeloid Leukemia Confers Prognostic Significance in Children and Young Adults with FLT3 /ITD Mutations

Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate

CD33 SNP Genotype and Splice Variation Are Associated with CD33 Cell Surface Expression and SGN-CD33A Pharmacokinetics

Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium

Synergistic Effect of SGN-CD33A and FLT3 Inhibitors in FLT3 /ITD Acute Myeloid Leukemia

Recurrent Copy Number Variants Are Highly Prevalent in Acute Myeloid Leukemia

Barriers to Successful Implementation of Precision Medicine to the Treatment of Refractory AML: Lessons Learned

CD33 DE2 Transcript Variant Encoded By Splicing Polymorphism Is Devoid of Antibody Binding Site and Lacks Response to CD33 Directed Antibody Drug Conjugates

Prolonged Azacitidine Exposure Alters Immunophenotype in Myeloid Leukemia Cell Lines

Functional Properties of Exon 17 KIT Mutations in Pediatric CBF AML Predict for Inferior Outcome and Enhanced Response to Tyrosine Kinase Inhibition: A Report from the Children's Oncology Group

Functional Evaluation and Clinical Implications of FLT3 J uxtamembrane Domain Short Variants in Pediatric AML

Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only